BUNTANETAP TARTRATE
Amnestic Mild Cognitive Impairment
Annovis Bio Inc.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Amnestic Mild Cognitive Impairment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Verubecestat Merck Sharp & Dohme LLC | Phase 3 | B |
Humulin R University of Southern California | Phase 2/3 | B |
ah110690 GE Healthcare | Phase 2 | B |
TEONANACATL Centre for Addiction and Mental Health | Phase 2 | CCC |
AQW051 Novartis Pharmaceuticals | Phase 2 | CCC |
mk-6240 Merck Sharp & Dohme LLC | Phase 1 | CC |
TACROLIMUS Sunnybrook Health Sciences Centre | N/A | D |
Same molecule, other indications
BUNTANETAP TARTRATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →